Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids)
Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169)
06/2002
06/18/2002US6407236 Tumor diagnosis; antiinflammatory agents; antiischemic agents; antidepressants
06/18/2002US6407214 Engineering human antibodies
06/18/2002US6407133 Treatment and prevention of reactive oxygen metabolite-mediated cellular damage
06/18/2002US6407111 Phenyl substituted pyridine and benzene derivatives
06/18/2002US6407108 1,2,4-triazolo(4,3-b)pyrido(3,2-d)pyridazine derivatives and pharmaceutical compositions containing them
06/18/2002US6407106 For therapy of inflammatory disturbances of the gastrointestinal tract
06/18/2002US6407104 Pyrrolo[1,2-a]pyrazine spla2 inhibitor
06/18/2002US6407088 Method of analgesia
06/18/2002US6407080 N-(pyrimidinyl)-aspartic acid analogs as interleukin-1β converting enzyme inhibitors
06/18/2002US6407067 Salts of thrombin inhibitors
06/18/2002US6407058 Phosphorylation of serine or threonine
06/18/2002US6406865 Method of inhibiting interaction of cells bearing CCR2 by Anti-CCR2 amino-terminal domain antibodies
06/18/2002US6406694 Anti-CCR2 antibodies
06/18/2002US6406681 Propellents and drugs
06/18/2002CA2356812A1 Tnf-alpha production inhibitor comprising kavalactone as an active ingredient
06/18/2002CA1341370C Fused polycyclic compounds, methods of manufacture, and their use as paf antagonists, antihistamines and/or antiinflammatory agents
06/14/2002WO2001041709A2 Methods for treating cell death diseases and inflammation
06/14/2002CA2393722A1 Methods for treating cell death diseases and inflammation
06/13/2002WO2002046458A2 Nucleic acids of the human abca5, abca6, abca9, and abca10 genes, vectors containing such nucleic acids and uses thereof
06/13/2002WO2002046426A2 Polypeptide sequences of drug metabolizing enzymes and polynucleotide sequences coding therefor
06/13/2002WO2002046423A2 Protein derived from the melanin-concentrating hormone (mch), corresponding nucleic acids and their use for preparing medicines
06/13/2002WO2002046418A2 Lipid-associated molecules
06/13/2002WO2002046412A2 Regulation of angiogenesis with zinc finger proteins
06/13/2002WO2002046409A2 Proteins and nucleic acids encoding same
06/13/2002WO2002046386A2 Aspergillus ochraceus 11 alpha hydroxylase and oxidoreductase
06/13/2002WO2002046385A2 Enzymes
06/13/2002WO2002046384A2 Kinases and phosphatases sequences, and use thereof
06/13/2002WO2002046383A2 Protein modification and maintenance molecules
06/13/2002WO2002046382A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
06/13/2002WO2002046373A1 Method of collecting placental stem cells
06/13/2002WO2002046230A2 G-protein coupled receptors
06/13/2002WO2002046225A2 Use of sarp-1 for the treatment and/or prevention of scleroderma
06/13/2002WO2002046214A2 Immunomodulatory protein derived from the yaba monkey tumor virus
06/13/2002WO2002046197A1 Macroheterocylic compounds useful as kinase inhibitors
06/13/2002WO2002046193A2 Heterocyclic ether substituted imidazoquinolines
06/13/2002WO2002046192A2 Thioether substituted imidazoquinolines
06/13/2002WO2002046191A2 Urea substituted imidazoquinoline ethers
06/13/2002WO2002046190A2 Sulfonamido ether substituted imidazoquinolines
06/13/2002WO2002046189A2 Aryl ether substituted imidazoquinolines
06/13/2002WO2002046188A2 Amido ether substituted imidazoquinolines
06/13/2002WO2002046187A1 Analgesic diazabicyclo[4.3.0]nonanes
06/13/2002WO2002046184A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
06/13/2002WO2002046183A2 Indazolyl-substituted pyrroline compounds as kinase inhibitors
06/13/2002WO2002046178A2 Benzofuran and benzothiophene derivatives as selective cox-2 inhibitors
06/13/2002WO2002046171A2 Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
06/13/2002WO2002046170A2 Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
06/13/2002WO2002046168A1 Therapeutic benzimidazole compounds
06/13/2002WO2002046164A1 Therapeutic compounds
06/13/2002WO2002046158A2 Piperidine/piperazine-type inhibitors of p38 kinase
06/13/2002WO2002046154A1 Peroxisome proliferator activated receptor d activators
06/13/2002WO2002046147A2 Perturbed membrane-binding compounds
06/13/2002WO2002045750A1 Combination drugs
06/13/2002WO2002045737A2 Methods of treatment involving human mda-7
06/13/2002WO2002045734A1 Tahitian noni juice on cox-1 and cox-2 and tahitian noni juice as a selective cox-2 inhibitor
06/13/2002WO2002045728A1 Cosmetic and/or dermopharmaceutical preparations containing leaf extracts of the plant argania spinosa
06/13/2002WO2002045723A2 Inflammatory cytokine secretion inhibition with modified mammalian blood
06/13/2002WO2002045711A1 Use of anti-muscarinic agents and calcium channel blockers in combination
06/13/2002WO2002045703A2 Mixtures or organic compounds for the treatmentof airway diseases
06/13/2002WO2002045702A2 Tricyclic therapeutics for chemokine mediated diseases
06/13/2002WO2002045688A2 Composition for treatment of inflammatory disorders
06/13/2002WO2002045687A2 Topical alcoholic solution of a salicylic acid derivative and acemannan
06/13/2002WO2002045681A2 Solid polyunsaturated fatty acid compositions
06/13/2002WO2002045652A2 Tyrosine kinase inhibitors
06/13/2002WO2002028842A3 Diazacycloalkanedione derivatives which are useful as lfa-1 antagonist
06/13/2002WO2002028825A3 Aminopyridinyl-, aminoguanidinyl- and alkoxyguanidinyl- substituted phenyl acetamides as protease inhibitors
06/13/2002WO2002022848A3 Compositions comprising mixtures of human cytokines and methods of producing the same
06/13/2002WO2002020038A3 Method for down-regulating ige
06/13/2002WO2002017857A3 Methods and compositions for inhibiting angiogenesis
06/13/2002WO2002014315A3 Substituted pyrazoles
06/13/2002WO2002012339A3 Sequences for integrin alpha-8
06/13/2002WO2002012245A3 Azabicyclic derivatives and their therapeutic use
06/13/2002WO2002008222A3 HETEROARYL-β-ALANINE DERIVATIVES AS ALPHA 4 INTEGRIN INHIBITORS
06/13/2002WO2002008219A3 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
06/13/2002WO2002007712A3 Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs
06/13/2002WO2002003962A3 Drug delivery system for poorly water soluble drugs
06/13/2002WO2001096330A3 Thrombin receptor antagonists
06/13/2002WO2001090104A3 -(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases
06/13/2002WO2001085257A3 Opioid antagonist compositions and dosage forms
06/13/2002WO2001070233A3 Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
06/13/2002WO2001064889A3 Tnf-alpha variants for the treatment of tnf-alpha related disorders
06/13/2002US20020072631 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
06/13/2002US20020072630 Therapy
06/13/2002US20020072615 Useful as intermediate in the preparation of certain small molecules that are useful in therapy or prophylaxis of inflammatory and immune cell-mediated disease
06/13/2002US20020072610 Useful as an intermediate in the preparation of certain small molecules that are useful in therapy or prophylaxis of inflammatory and immune cell-mediated diseases
06/13/2002US20020072609 Process for preparing arylacetylaminothiazoles
06/13/2002US20020072607 Inhibit binding of integrins to their ligands and are of use in prophylaxis and therapy of of immune or inflammatory disorders, or disorders including inappropriate growth or migration of cells
06/13/2002US20020072529 For therapy and prophylaxis of cerebral apoplexy and craniocerebral trauma
06/13/2002US20020072526 Orally active salts with tyrosine kinase activity
06/13/2002US20020072523 For therapy of inflammatory and immune diseases
06/13/2002US20020072517 Substituted cyclic amine metalloprotease inhibitors
06/13/2002US20020072510 3-nitrogen-6,7-dioxygen steroids and uses related thereto
06/13/2002US20020072509 Methods for the treatment of a traumatic central nervous system injury
06/13/2002US20020072494 Angiogenesis inhibitor, K1-5 (protease-activated kringles 1-5) genetically engineered so it can be secreted from cells in which it is expressed; contains a secretory signal peptide and a pre-activation peptide derived from plasminogen
06/13/2002US20020072491 Homology to members of the myosin light chain kinase subfamily
06/13/2002US20020072485 Administering prior to the impairment of glucose and/or oxygen to the brain an NMDA receptor subunit (NR2B) selective NMDA antagonist to inhibit neuronal damage (ischemia)
06/13/2002US20020071857 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor
06/13/2002US20020071849 A41L protein or a chemokine-binding fragment thereof; detecting an interaction of the chemokine-binding molecule with a chemokine; antiinflammatory agents
06/13/2002US20020071843 Targeted therapeutic agents
06/13/2002US20020071822 Polymer comprising a backbone comprising ester, thioester, or amide linkages, and wherein the backbone comprises one or more groups that will yield a biologically active compound upon hydrolysis of the polymer.
06/13/2002DE10059864A1 Substituierte Amino-furan-2-yl-essigsäure- und Amino-thien-2-yl-essigsäure-Derivate Substituted amino-furan-2-yl-acetic acid and amino-thien-2-yl-acetic acid derivatives
1 ... 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 ... 1272